Prevalence of obesity has steadily increased over the past three decades both in the United States and worldwide. Recent studies have shown the role of dietary polyphenols in the prevention of obesity and obesity-related chronic diseases. Here we evaluated the impact of commonly consumed polyphenols, including green tea catechins and epigallocatechin gallates, resveratrol, and curcumin, on obesity and obesity-related-inflammation. Cellular studies demonstrated that these dietary polyphenols reduce viability of adipocytes and proliferation of preadipocytes, suppress adipocyte differentiation and triglyceride accumulation, stimulate lipolysis and fatty acid β-oxidation, and reduce inflammation. Concomitantly, the polyphenols modulate signaling pathways including the AMP-activated protein kinase, peroxisome proliferator activated receptor γ, CCAAT/enhancer binding protein α, PPAR gamma activator 1-alpha, sirtuin 1, sterol regulatory element binding protein-1c, uncoupling proteins 1 and 2, and nuclear factor kappa B that regulate adipogenesis, antioxidant and anti-inflammatory responses. Animal studies strongly suggest that commonly consumed polyphenols described in this review have a pronounced effect on obesity as shown by lower body weight, fat mass, and triglycerides through enhancing energy expenditure and fat utilization, and modulating glucose hemostasis. Limited human studies have been conducted in this area, and are inconsistent about the anti-obesity impact of dietary polyphenols, probably due to the various study designs and lengths, variation among subjects (age, gender, ethnicity), chemical forms of the dietary polyphenols used and confounding factors such as other weight reducing agents. Future randomized controlled trials are warranted to reconcile the
Introduction
The prevalence of obesity has steadily increased over the past three decades both in the United States and worldwide [1] . Obesity has been associated with co-morbid metabolic and chronic diseases, such as type-2 diabetes, heart diseases, hypertension and several forms of cancer, and has added tremendous burden to the health care system [1] . Obesity is a multifactorial complex disease influenced by lifestyle, behavioral, environmental as well as genetic factors. Obesity emanates from energy imbalance due to excess caloric intake relative to energy expenditure; the latter primarily reflects sedentary lifestyle and lack of physical activity [2, 3] . Other obesigenic factors such as genetic susceptibility, family history and gene-environment interactions all contribute to the development of obesity [2, 3] .
Obesity is defined by excess adipose mass and adipose tissue expansion, which occurs through adipocyte hypertrophy and hyperplasia [4] . Adipose tissue is an important energy storage organ and has only been progressively recognized over the past two decades as a key endocrine organ with active metabolism [5] . Indeed, adipose endocrine function is critical to overall energy balance and homeostasis with adipocyte-derived pro-and anti-inflammatory adipokines playing key roles. When the production and secretion of pro-inflammatory adipokines prevail, systemic inflammation, insulin resistance and obesity-related metabolic disorders arise [5] . In addition to adipocytes, stroma vascular cells -preadipocytes, adipose stem cells -and immune cells within adipose tissue such as macrophages and lymphocytes are rich sources of adipokines and contribute to obesity-associated inflammation [5] . Thus, obesity is a chronic low-grade inflammation.
This inflammation-associated obesity can be prevented or even reversed with weight reduction that can be achieved via energy restriction and increased physical activity [6] . Some studies demonstrated that physical activity directly reduced inflammation, others reported that the anti-inflammatory effects of physical activity are indirectly caused by reduced adiposity, which in turn reduces fat mass and fat-derived inflammatory adipokines [7] [8] [9] . Moreover, consumption of foods rich in bioactive anti-inflammatory compounds, such as omega-3 fatty acids and polyphenols, has been documented to decrease inflammation [4, 10] . Beneficial effects of some diets such as the Mediterranean diets are attributed for the most part to the significant amounts of bioactive components with recognized anti-inflammatory and anti-oxidant properties [4, 10] . Indeed, several cell, animal and human studies provide strong evidence that dietary bioactive compounds act as anti-oxidant and anti-inflammatory agents to increase thermogenesis and energy expenditure while decreasing inflammation and oxidative stress, further supporting progress towards weigh loss and/or decreased metabolic disorders [4, 5, 11] . In a systemic review by Esfahani et al. [5] , the authors reported that daily consumption of mixed fruits and vegetable supplements significantly increases serum levels of antioxidant pro-vitamins and vitamins (β-carotene, vitamins C and E) and folate and reduces homocysteine and markers of oxidative stress [12] . These findings emphasize the beneficial effects of food components and further support the dietary recommendations for Americans that emphasize diets rich in fruits and vegetables for the prevention of chronic diseases including obesity [13] .
Laboratory studies indicate that the anti-obesity effects of polyphenol-rich diets may be attributed to the ability of polyphenols to interact, directly or indirectly, with adipose tissues (preadipocytes, adipose stem cells, and immune cells). Therefore, in this review, we discuss possible mechanisms for the inhibitory effects of commonly consumed dietary antioxidants, namely epigallocatechin gallate (EGCG) and green tea extracts, resveratrol and curcumin, on obesity based on cell, animal, and human studies.
Epigallocatechin gallate and green tea extract
Green tea is made from the dried leaves of the Camellia Sinensis plant. Different from fermented black tea and partially fermented oolong tea, green tea is a non-fermented tea that is produced from direct drying of fresh green tea leaves by hot steam and air. During this process, polyphenol oxidase is inactivated and polyphenols are preserved [14] . Compared to black tea and oolong tea, green tea contains the highest amount of green tea catechins [15] , the major polyphenols in green tea that constitutes about 35% of its total dry weight [14] . A 2-gram bag of green tea contains about 500 mg of green tea catechins. The most abundant green tea catechins are (−)-epigallocatechin gallate (EGCG), which accounts for about 68-69% of green tea catechins, followed by (−)-epigallocatechin (EGC, circa 15-18%) (−)-epicatechin gallate (ECG, circa 5-6%), and (−)-epicatechin (EC, circa 2-5%) [16] .
The anti-obesity potential of green tea catechins, particularly EGCG, has been shown in cell culture, animal and human studies. Table 1 lists the in vitro activities of EGCG and green tea extracts (GTE) in inhibiting preadipocyte differentiation, decreasing adipocyte proliferation, inducing adipocyte apoptosis, suppressing lipogenesis, and promoting lipolysis and fatty acid beta (β)-oxidation [17-28].
EGCG (10-100 µM) and with lower potencies, EC and EGC, induce dose-and timedependent decrease in adipocyte viability [28, 29] and cell cycle arrest at the G0/G1 phase [19] . At lower concentrations (0-10 µM) EGCG induced G 2 /M growth arrest in a dosedependent manner in mature 3T3-L1 adipocytes [17] . Concurrently, EGCG (0-400 µM) and less potently ECG, EGC and other catechins induce apoptosis in murine 3T3-L1 preadipocyte [29] and mature 3T3-L1 adipocytes [26] as shown by DNA fragmentation [29] and increased caspase-3 activity [29] . Furthermore, EGCG (0.5-10 µM) inhibits preadipocyte differentiation and at higher concentrations (50-200 µM) [17, 21, 24, 26, 28] , cellular triglyceride accumulation in adipocytes in a dose-and time-dependent manner.
EGCG-mediated suppression of adipocyte differentiation may be attributed to its impact on genes playing crucial roles in adipocyte differentiation ( Figure 1 ). Peroxisome proliferator activator receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα) are two key regulators of adipocyte differentiation that orchestrate the expression of adipogenic and lipogenic genes; these genes include acetyl-coenzyme A carboxylase (ACC) that converts acetyl-CoA to malonyl-CoA, a building block for fatty acid synthesis and an inhibitor for fatty acid oxidation [30] , and the transcriptional factor sterol regulatory element-binding protein 1c (SREBP-1c) that enhances lipogenesis and adipogenesis [21] . EGCG's effect on adipocyte differentiation is accompanied by down-regulation of the expression of PPARγ and C/EBPα at the mRNA and protein levels [17] and activation of AMP-activated protein kinase (AMPK), a suppressor of PPARγ and C/EBPα expression [17, 20] .
Complementing EGCG's effect on adipocyte differentiation is EGCG's ability to upregulate lipolysis and thermogenesis [24] . EGCG was found to increase glycerol release and the expression of hormone sensitive lipase and carnitine palmitoyltransferase-1 (CPT-1) that is involved in fatty acid β-oxidation in 3T3-L1 cells [17] . The mRNA levels of uncoupling protein (UCP)-2, a key protein in fat-supported thermogenesis, was increased by EGCG (0-10 µM) in a dose-dependent manner [25] .
In addition to the effects of EGCG described above, reduced expression of resistin [27] , an adipocyte-derived inflammatory adipokine that is associated with insulin resistance and increased risk of cardiovascular disease (CVD) [ Table 2) .
Although the etiology of obesity is still not well studied, emerging evidence has indicated the effect of chronic inflammation-induced excessive ROS or oxidative stress on the development of obesity [55] . Alvehus et al. reported that the human visceral fat depot proposes a unique inflammatory profile and it may directly contribute to chronic systemic inflammation in obese humans [55] . Therefore, lowering the levels of ROS or oxidative stress becomes an important strategy to deal with obesity-related alteration. More recently, it has been suggested that such anti-obesity benefit of green tea supplementation may be, in part, meditated through its ability to act as an antioxidant and singlet oxygen quencher, therefore inhibiting the destructive effects of ROS and suppressing inflammation in the development of obesity [38, 39, 43, 45, 51].
For instance, Shen et al. reported that compared to the female rats in low-fat diet, animals fed a high-fat diet for 8 months had increased percentage of fat mass (FM) and serum insulin-like growth factor-I (IGF-I) and leptin levels and reduced percentage of fat-free mass (FFM) and serum adiponectin levels. Supplementation of green tea polyphenols (GTP) in drinking water for 4 months in the obese rats decreased body weight (BW) and percentage of FM, increased percentage of FFM, bone mineral density and strength, and glutathione peroxidase (GPX) protein expression, and suppressed serum IGF-I, leptin, and proinflammatory cytokines in the obese rats. This study demonstrates GTP supplementation benefited body composition and bone properties in obese rats possibly through enhancing antioxidant capacity and suppressing inflammation [51] . Based on the obesity-related gene array analysis, the same research team further demonstrated that GTP supplementation has potent effects on increasing adiposity or fat accumulation in obese middle-aged female rats through enhancing obesity-related anorectic genes and anti-oxidative stress capacity, suppressing obesity-related orexigenic genes and pro-inflammation activity, and modulating estrogen-associated action [43] .
The effect of green tea administration on obesity-related parameters has been reported by a number of human studies (Table 3 ) . Green tea consumption, in the forms of EGCG or GTE with or without caffeine, by obese subjects decreased BW, body mass index (BMI), and waist and hip circumference, total body fat, and abdominal visceral and subcutaneous fat area. On the other hand, the impact of green tea supplementation on lipid profiles (total cholesterol, low density lipoprotein-cholesterol (LDL-C), high density lipoproteincholesterol (HDL-C), TAG, TG, or free fatty acids (FFA), glucose homeostasis (glucose, insulin sensitivity, or HOMA-IR), as well as blood pressure (systolic blood pressure (SBP) or diastolic blood pressure (DBP)) in obese subjects seem to be inconsistent by showing either an improvement or no effect (Table 3) . The difference in lipid profiles, glucose homeostasis, and blood pressure may be related to different periods of weight management (weight loss period vs. weight maintenance period) and the health status of subjects. Nevertheless, authors commented that green tea may facilitate weight loss by enhancing energy expenditures and fatty acid oxidation, confirming the preclinical studies (Table 2) .
In human studies, not all studies have found positive results for obesity-related measures. Green tea administration has also shown no influence on BW, BMI, FM, and waist and hip circumference. For example, Diepvens et al. reported that 12-week green tea supplementation to a low-energy diet, independent of habitual caffeine intake, had no effect on measures of BW or body composition in overweight women at 4 weeks or 3 months [65] . Similar non-significant findings was observed in Hill's study that there was no difference in BW, BMI, waist circumference, abdominal fat and intra abdominal adipose tissue between the placebo group and the EGCG-supplemented group in overweight/obese postmenopausal women who attended regular aerobic exercise [67] . In a randomized, double-blinded, placebo-controlled trial in Taiwan, Hsu et al. reported there was no statistical difference in % reduction in BW, BMI, and waist circumference between the placebo and the GTEsupplemented (491 mg catechins) groups after 12 weeks of treatment [68] . Unlike Diepvens' or Hill's studies, there was no other weight control maneuver in Hsu's study. Furthermore, lack of beneficial impact of GTE on obesity was also reported by Matsuyama et Several systemic reviews have been published in the past four years. Based on a metaanalysis of 11 studies, Hursel et al. concluded that catechin or an EGCG-caffeine mixture contained in green tea had a small effect on weight loss and weight maintenance [77] . Phung et al. reported that participants in intervention groups who received green tea catechins (GTC) in combination with caffeine had a decreased BW and waist circumference, compared with the control groups containing similar amounts of caffeine [78] . However, in a recent meta-analysis analyzing randomized controlled trials (RCT) (n=14) with at least 12 week's duration, Jurgens et al. reported that green tea administration appears to induce a small, statistically non-significant weight loss in overweight or obese adults. Because the amount of weight loss is small, Jurgen et al. commented that it is not likely to be clinical important. In addition, green tea had no significant effect on the maintenance of weight loss [79] .
The discrepancies among these clinical studies employing green tea may be due to the varieties of study designs (uncontrolled design, RCT, crossover), the length of study (24 hours -24 weeks), age and gender of subjects, the ethnicity of subjects, the formulations of green tea supplement (EGCG, GTC, GTE), and the presence or absence of weight control factors (i.e., caffeine, exercise, low-caloric diet), etc.
In summary, cellular and animal studies have shown that dietary supplementation with EGCG or GTE is a potentially viable nutritional strategy for the prevention of obesity. However, the low bioavailability of GTC along with potential confounders (i.e., ethnicity and genetic effects, habitual caffeine or GTC intake, etc.) may have contributed to the inconsistent outcome of human studies. More well-controlled, long-term human studies using green tea supplementation are warranted.
Resveratrol
Resveratrol (3, 4', 5-trihydroxystilbene), a phytoalexin, is a naturally occurring polyphenolic compound. It is produced by some plants in response to strenuous conditions such as fungal infection, injuries or UV irradiation [80] . Resveratrol is found in grapes, red wine and some berries. Resveratrol exists in two isomeric forms: cis-and trans-resveratrol. Transresveratrol is naturally found in grape, mainly in the skin but not in flesh; it is also present in the leaf epidermis of the grape vine [81] . Trans-resveratrol is the main form of resveratrol found in red grape juice (3.38 mg/L) [82] . Other than grapes, trans-resveratrol is found in 72 other plant species and in foods like mulberries, peanuts and in small amounts in cocoa [83, 84] . Cis-resveratrol is present in red wine but not grapes; trans-resveratrol is converted to cis-form by yeast during fermentation or is released from trans-resveratrol polymer vinferins. Cis-resveratrol can also be formed by exposure of trans-resveratrol to UV irradiation [85] . Both trans-and cis-forms of resveratrol have similar biological and antioxidant activities. Since cis-resveratrol is not commonly found in foods and is unstable, trans-resveratrol has been studied more extensively [86] and is the subject of this review.
Many studies using adipocytes have demonstrated that resveratrol has an anti-obesity potential by inhibiting preadipocyte differentiation, decreasing adipocyte proliferation, inducing adipocyte apoptosis, decreasing lipogenesis, and promoting lipolysis and fatty acid β-oxidation ( Similar to EGCG, resveratrol induces apoptosis of adipocytes, decreases their proliferation, and causes cell cycle arrest at a concentration range 10 to 100 µM [93] . At these concentrations resveratrol also inhibits preadipocyte differentiation in a dose-dependent manner with a concomitant suppression of expression of PPARγ, C/EBPα, and fatty acid binding protein 4 (FABP4), and other biomarker proteins (e.g., AMPK, SIRT1, FOXO1) for adipocytes [88, 90, 92, 93] . Down-regulation of PPARγ and C/EBPα expression is attributed to resveratrol-mediated activation of AMPK and SIRT1; the latter deacetylates and activates forkhead box protein O1 (FOXO1), a protein that binds to the promoter sites of PPARγ and further prevents its transcription [107] .
Resveratrol also decreases lipogenesis in adipocytes. In 3T3-L1 cells resveratrol (10-100 µM) dose-dependently decreases intracellular triglyceride (TG) accumulation [88, 92, 93, 96] with concomitant down-regulation of lipogenic genes including fatty acid synthase (FAS), lipoprotein lipase (LPL), SREBP1c, and stearoyl-CoA desaturase-1 (SCD1) [96, 99] . Resveratrol-activated AMPK phosphorylates and further inactivates acetyl-CoA carboxylase [108] and consequently, blocks the production of malonyl-CoA, a stimulator of lipogenesis.
The anti-adipogenic activity of resveratrol is furhther enhanced by resveratrol-stimulated lipolysis. In mature 3T3-L1 and human adipocytes resveratrol (100 µM) significantly increased free fatty acid (FFA) release concomitant with 5-and 12-fold rises in the mRNA and protein levels of adipose triglyceride lipase (ATGL), respectively [95] The anti-obesity property of resveratrol may also stem from its effect on antiinflammatory response in adipose tissue. Resveratrol (0.1-10 µM) significantly reduced nuclear factor-κB (NF-κB) activation and the expression and release of interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-α) in RAW 264.7 macrophages and 3T3-L1 cells [91] . Resveratrol at up to 50 µM also suppressed the expression of matrix metalloproteinase (MMP)-2 and MMP-9 [92] and TNF-α-induced release of IL-6, monocyte chemoattractant protein-1 (MCP-1)
[100] and other adipokines [87] in 3T3-L1 cells.
The impact of resveratrol on obesity in animal studies was mainly based on a diet-induced obese animal model ( [116] and glucose homeostasis [113] . These observations of the anti-obesity effects of resveratrol seem to be consistent with findings from other animal models, including leptin-deficient ob/ob mice (a model of peripheral neuropathy of type II diabetes and obesity) [118] or obese (fa/ fa) Zucker rats (a spontaneous genetic obesity model) [117, 122] . On the other hand, Nagao et al. recently reported that the short-term resveratrol supplementation in a diet enhances fat metabolism (by sharing metabolism for carbohydrate and protein) along with unchanged lipid parameters on male OLETE rats (a model of type II diabetes with obesity) [120] . DalPan et al. also confirmed that dietary resveratrol prevented weight gain in non-human primate, as evidenced in a marked reduction of energy intake, an elevation of resting metabolic rate and fat mobilization [115] . There were few exceptions where resveratrol supplementation failed to induce changes in body weight [112] , lipogenesic enzymes [111] , and blood lipid profiles and glucose [119] . The discrepancy could be due to the duration of study, dosage of resveratrol, and age of animals.
The anti-obesity effect of resveratrol in animals seems to be mediated through stimulation of fat oxidation and metabolism [106, 113, 120, 122] or suppression of adipogenic gene expression (i.e., PPAR, C/EBPα, SREBP-1c, FAS, LPS, fatty acid binding protine (aP2), leptin) [112, 118] . In addition, resveratrol administration not only inhibits obesity-induced chronic inflammation (i.e., expression of TNF-α, interferon (IFN)-γ, IFN-β, and IL-6 along with downstream signaling molecules) [114, 118, 122] and oxidative stress (decreased thiobarbituric acid reactive substances (TBARS), malondialdehyde (MDA), and glutathione disulfide (GSSG)) [116, 117] , but also enhances anti-oxidant defense capacities (increased liver superoxide dismutase (SOD), GPX, catalase)) [114, 116] .
Several clinical studies examined the effects of resveratrol on obesity-related energy expenditure, fat oxidation, plasma lipid profiles, glucose hemostasis, and inflammation (Table 4) [123] [124] [125] [126] [127] . In a randomized, placebo-controlled, double-blinded crossover study, Timmers et al. reported beneficial effects of 30-day resveratrol supplementation on the metabolic profiles in healthy obese men, which appears to mimic the effects observed during calorie restriction. The modest metabolic changes included improvement in glucose hemostasis (decreased glucose, insulin, HOMA-IR and leptin) and lipid profile (decreased plasma FA, glycerol, and TG) [124] .
In a triple-blinded, randomized, parallel, dose-response, placebo-controlled study, TomeCarneiro and colleagues reported that the intake of one capsule/day of Stilvid® (a resveratrol-rich grape supplement containing grape polyphenols including 8 mg resveratrol) significantly reduced LDL-cholesterol, oxidized LDL, and ApoB in patients undergoing primary prevention of CVD with gold-standard medication [118] . In a follow-up one-year study, Tome-Carneiro et al. found a resveratrol-rich grape supplement improved the inflammatory and fibrinolytic status in patients who were on statins for primary prevention of CVD and at high CVD risk [125] . In a recent study by the same team, authors further demonstrated that resveratrol supplementation to patients resulted in increased serum adiponectin, an anti-inflammatory cytokine, and decreased thrombogenic plasminogen activator inhibitor type 1 (PAI-1) by modulating six key inflammation-related transcription factors along with 27 extracellular-space acting genes involved in inflammation, cell migration, and T-cell interaction signals [126] . However, in all of the studies by TomeCarneiro and colleagues, the authors were not able to rule out the potential synergistic effect of resveratrol with the rest of grape polyphenols and/or statins in patients with coronary artery disease [118] [119] [120] .
A recent randomized, placebo-controlled clinical trial by Poulsen et al. did not seem to support the anti-obesity potential of resveratrol in healthy obese men; no effect was seen on blood pressure, resting energy expenditure, oxidation rates of lipid, ectopic or visceral fat content, or inflammatory and metabolic biomarkers [123] . The lack of effect may be due to a relative short-term study intervention.
In summary, evidence from these limited clinical studies combined with the results from in vitro and animal studies indicate that potential anti-obesity effects of resveratrol may be achieved through dietary supplementation. However, the optimal doses and study period for the anti-obesity potential of resveratrol remain to be determined.
Curcumin
Curcumin, a yellow-colored hydrophobic polyphenol, is the principal curcuminoid of the spice turmeric, the ground rhizome of the herb Curcuma longa [128] . Curminn comprises 2-8% of turmeric [129] . Turmeric known for its anti-inflammation, anti-carcinogenesis, antiobesity, anti-angiogenesis, and anti-oxidant activities [130] has been used as a dietary spice, coloring agent in foods and textiles. The Asian Indian population has consumed curcumin at doses up to 100 mg/day for many years [131, 132] . Recent human studies indicate that consumption of 8 g/day doesn't show side effects [133] .
Many recent studies [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] have demonstrated that, similar to EGCG and resveratrol, curcumin has an anti-obesity property through inhibiting preadipocyte differentiation, suppressing lipogenesis, promoting fatty acid oxidation, and reducing inflammatory response in adipose tissue [130] . Curcumin also exerts anti-inflammatory effects on macrophages and adipocytes [141, 142] . Recruitment and infiltration of macrophages into expanded adipose tissue can increased its local inflammatory response. Inhibitory effect of curcumin on chemotaxis and release of MCP-1 from adipocytes [130, 135] may partially contribute to its anti-inflammatory activity. When RAW 264.7 macrophages were treated with adipose tissue-conditioned medium containing 0.1 to 10 µM curcumin, the migration of macrophages was inhibited in a dosedependent manner [142] . In addition, curcumin decreases the expression and release of inflammatory factors from adipocytes through inhibiting NF-κB activity and its nuclear translocation [141] . Shao et al fed male C57BL6J mice with high fat diets in combination with or without curcumin (4 g/ kg diet) for 28 weeks [130] . After isolating primary adipocytes from epididymal fat pads, they demonstrated that NF-κB expression levels in both whole cell lysates and nuclear extract were significantly lowered by curcumin in mice fed high fat diet. As a result of NF-kB down-regulation, curcumin at 1 to 20 µM significantly decreased the expression and release of downstream IL-6, TNF-α, MCP-1 from 3T3-L1 cells [128, 137, 142] .
Several preclinical studies have shown the beneficial effects of dietary curcumin in obesityrelated metabolic disorders in animals. For example, curcumin supplementation was shown to lower serum and liver cholesterol levels in rats fed with a cholesterol-rich diet [145] . In a rat model of high fat diet-induced obesity, authors reported curcumin supplementation significantly decrease plasma FFA [146] In addition to the rodent models, other types of animals have also been used to examine the effect of curcumin on obesity-related metabolic disorders (Table 5) [136, 140, 145-156]]. Jang et al. [154] reported the beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Compared to the control, hamsters fed with curcumin for 10 weeks had significantly lower FFA, total cholesterol, TG, leptin, and HOMA-IR but increased plasma HDL-C, Apo A-1, and paraoxonase (PON). In addition, relative to the control group, curcumin-supplemented group had lower hepatic cholesterol and TG levels, FFS, HMG-CoA reductase, and acyl-coenzyme A: cholesterol acyltransferase (ACAT) activities along with increased fatty acid β-oxidation activity [154] . Mesa and colleagues [157] demonstrated that oral administration of turmeric extract (which primary contain curcumin) prevented the oxidation of red blood cell membranes and lipid peroxidation in liver microsome in rabbits fed an atherosclerotic diet [157] . Similarly, Leray et al. concluded that highly bioavailable curcumin extract lowered plasma aminoalkyl glucosaminide 4-phosphate (AGP) concentration as well as obesity-related inflammatory cytokines [156] .
There are limited clinical trials to investigate the effect of curcumin on obesity-related parameters. In a pre-post study, Ramı´rez-Bosca´ reported that oral administration of 10 mg curcumin extract per day for 30 days to 8 human subjects elevated HDL-C and apo A as well as lowered LDL-C, apo B and apo B/apo A ratio [158] . The same research team also found that 10 mg curcumin (twice/day) for 15 days significantly suppressed the levels of plasma fibrinogen in study subjects, which may reduce the risk for coronary disease [159] . In a randomized, double-blinded, placebo-controlled trial, Baum et al. [160] investigated the effects of curcumin consumption on the serum lipid profile in elderly men and women. Authors concluded that neither dose of curcumin (1g/day or 4 g/day) significantly affected blood TAG, total LDL, or HDL-C over 1 month or 6 months. However, the concentrations of plasma curcumin and serum cholesterol were positively and significantly correlated. Such insignificant findings of curcumin in Baum's study may be due to the following reasons: (i) a relative small sample size, (ii) the relatively low absorption efficiency of curcumin, or (iii) subjects not suffering hypercholesterolemia or provided a special diet (a ceiling effect) [160] .
Evidence from cellular and animal studies suggest the beneficial effects of curcumin on obesity and related metabolic disorders. These studies show that curcumin reduces BW, lowers TG synthesis, increases basal metabolic rate and FA oxidation, and improves insulin sensitivity, through its ability to act as an antioxidant or antiinflammatory mediator, therefore suppressing the destructive effects of oxidative stress or inflammation. However, translational studies from animal observation to human clinical trials are needed to verify such anti-obesity benefits of cucurmin. Figure 1 illulstrates the potential mechanisms of dietary polyphenols (GTC, resveratrol, and curcumin) on anti-obesity. Many lines of research indicate that dietary polyphenols prevent obesity development through the following possible mechanisms: 1) lower food intake; 2) decrease lipogenesis; 3) increase lipolysis; 4) stimulate fatty acid β-oxidation; 5) inhibit adipocyte differentiation and growth; and 6) attenuate inflammatory responses and suppress oxidative stress. GTC, especially EGCG, may lower food intake by increasing the production and release of cholecystokinin with hunger-suppressive effects [28] . EGCG can decrease lipid digestion and absorption by decreasing activities of digestive enzymes and lipid emulsification [14, 161] . Green tea catechins, resveratrol and curcumin can decrease fat accumulation in adipocytes through activating AMPK, inhibiting ACC activation, and down-regulating the expression of lipogenic genes such as FAS, SCD1, and SREBP-1c [20, 28, 96, 99] .
Potential mechanisms of action
These polyphenols also increase lipolysis and stimulate fatty acid β-oxidation through upregulating hormone sensitive lipase (HSL), UCPs, CPT-1 and PGC-1α [24, 25, 27, 95, 136] . These dietary polyphenols can decrease the proliferation of preadipocytes, induce their apoptosis, and promote cell cycle arrest. Green tea catechins, resveratrol and curcumin down-regulate the expression of key genes involved in adipocyte differentiation including C/ EBPα, PPARγ and aP2 [17, 88, 90, 134, 136] . They also induce G0/G1 and G2/M cell cycle arrest [17, 19, 93] and apoptosis of adipocytes as shown in increase of DNA fragmentation and caspase-3 activation. Inflammatory responses are suppressed by these polyphenols. The expression and secretion of pro-inflammatory resistin, PAI-1, IL-6, TNF-α, MCP-1, MMPs are inhibited by green tea catechins, resveratrol and curcumin, which may be partially attributed to inactivated NF-κB and MAPK [43, 51, 91, 100, 128, 137, 141, 142]. These polyphenols can also decrese oxidative stress and increase anti-oxidant capacity in adipose tissue.
Although the underlying mechanism for the polyphenol effects are still unclear, limited studies have shown that such effects may be mediated by a receptor or intracellular Ca, at least in the case of EGCG. For example, EGCG is incorporated into cytoplasma and further transported into nuclei in L-929 cells [162] . Uptake of EGCG by HT-29 cells is via a passive diffusion process [163] . EGCG can bind on its receptor, 67 kDa laminin receptor, on cancer cells and activate subsequent signaling molecules and anti-cancer activities including decreasing cell viability, inducing apoptosis and altering intracellular Ca 2 + [164, 165] . Few studies have investigated the initial mechanisms of EGCG in regulating lipid metabolism in adipocytes. Hsiech and colleagues reported that 67 kDa laminin receptor was expressed in 3T3-L1 and C3H10T1/2 adipocytes. EGCG binding to this receptor could inhibit insulin stimulation of adipocyte glucose uptake; the inhibitory effect was blocked by the receptor antibody [166] . In terms of resveratrol, many studies have demonstrated that resveratrol inhibits adipocyte differentiation and de novo lipogenesis, and stimulates lipolysis in adipocyte in a Sirt1-dependent manner or via activation of AMPK [88, 167, 168] . However, receptors for binding resveratrol to adipocytes and mechanisms for adipocytes uptake of resveratrol are unknown. More studies are required to investigate the specific mechanisms mediating initial resveratrol effects in adipocytes. Regarding curcumin, increased curcumin content in adipocytes was positively correlated with enhanced anti-adipogenic ability [169] . However, few studies have investigated the binding receptors, uptake or signaling mechanisms of curcumin in adipocytes.
We noted that the 3T3-L1 cells have been used in the majority of the in vitro studies presented here to study the effects of polyphenols on obesity. Use of 3T3-L1 cells has been used for decades as a good model for adipose tissue development. They present, however, some limitations. In some instances, the 3T3-L1 cells do not express adequate levels of certain adipocyte-specific genes and some other metabolic genes at the degree expressed in whole adipose tissue. Also their embryonic nature makes them more suitable to study adipose tissue development rather than adult or postnatal adipose tissue metabolism. Finally, these cells do not represent the complex and diverse cell type populations, the microvascular system or the extracellular matrix of the whole adipose tissue.
Summary and future research
Obesity is a complex and multifactorial condition of chronic inflammation and oxidative stress. Various strategies including lifestyle modifications (caloric restriction, increased physical activity, consumption of whole foods and/or dietary supplements), use of antiobesity drugs and in extreme cases, bariatric surgery are used for weight loss. Weight loss results in decreased fat mass, reduced local and systemic inflammation or reduced production and secretion of pro-inflammatory cytokines into the bloodstream, along with an elevation of antioxidant defense mechanism. In vitro and in vivo studies reviewed above demonstrate that green tea catechins and some of its components (especially EGCG), resveratrol and curcumin all exert anti-inflammatory and/or anti-oxidant effects in obesity-related metabolic alterations. These effects lead to one or more of the following outcomes: weight loss, decreased cellular and circulating lipids, increased basal metabolic rate, fatty acid oxidation, energy expenditure, and improved insulin sensitivity. Thus, the dietary polyphenols described in this review are potential nutritional strategies for the prevention of obesity and associated inflammation.
Published studies show that obesity-associated inflammation, a major contributor to metabolic disorders in humans, can be prevented or partially reversed by dietary polyphenols such as those reviewed herein. Mechanistically, these dietary polyphenols exert their additive and/or synergistic effects through one or more signaling and transcriptional mechanisms including those mediated by NF-κB, AMPK, PPARγ, and PGC-1α. However, most dietary polyphenols have relatively short half-lives once ingested due to rapid metabolism, so it is important that their consumption is maintained throughout the life span.
It was noted that these polyphenols have a low level of oral bioavailability in humans and research animals [170] [171] [172] [173] [174] [175] . After eating polyphenol-rich foods or taking dietary supplement, humans achieve peak plasma polyphenol concentrations at less than 10 µM [172, [174] [175] [176] [177] . In addition, polyphenols in human bodies are quickly modified and metabolized by tissue enzymes, especially hepatic enzymes [178, 179] . As a result, the circulating concentrations of free polyphenols are even lower [175] . Most in vitro studies used polyphenol concentration range between 10 and 200 µM, which is much higher than the physiological concentrations in humans [21, 144] . On the other hand, after giving animals high doses of polyphenols, the body weight and fat mass were significantly decreased [34, 136] . However, we did not observe dramatic reduction in body weight and fat mass in humans with high-dose polyphenols intake. Since the stability and bioavailability of most of these dietary polyphenols are affected by their cooking, processing and storage methods, additional studies are needed to further understand their optimal preparation as well as their bioavailability and mechanism of action within the whole body.
In addition to the relative low bioavailability of dietary polyphenols in humans, other factors, such as ethnicity, genetics, and lifestyles also need to be taken into account in designing clinical trials. Recent studies using nutrigenomic approach showed heterogeneity in individual responses to nutrients due to genetic factors such as single nucleotide polymorphisms. More importantly, we conclude that translational studies from animal observations to human clinical trials and ultimately community interventions are needed to further confirm the anti-obesity and/or anti-diabetic benefits of these polyphenols and foods rich in these bioactive compounds.
Abbreviation

ABCA1
ATP-binding cassette A1 Diagram illustrates the potential actions of dietary polyphenols, particularly green tea catechins (GTC), resveratrol and curcumin on obesity. GTC decrease food intake. These polyphenols increased energy expenditure through up-regulating uncoupled proteins (UCP1-3). They also decrease inflammatory response in adipose tissue, induce apoptosis and cell cycle arrest, inhibit adipogenesis and lipognenesis, stimulate lipolysis and fatty acid p-oxidation. These actions would lead to decreased adipocyte size and number, lowered fat mass% and decreased obesity risk. Abbreviation: ACC, acetyl-CoA carboxylase; C/EBPp, CCAAT/enhancer binding protein beta; CPT-1, carnitine palmitoyltransferase-1; DAG, diglyceride; DGAT, diglyceride acyltransferase; FA, fatty acid; FAS, fatty acid synthase; MAG, monoglyceride; PPARy, Peroxisome proliferator activator receptor gamma; TAG, triglyceride. Table 1 Effect of green tea catechins on obesity in cell studies Abbreviations: ABHD5, abhydrolase domain containing 5; ACC, acetyl-Coenzyme A carboxylase; ACO, acetyl-CoA oxidase; Adcyap1r1, adenylate cyclase activating polypeptide 1 receptor 1; Adrb1 Adrenergic, beta-1-, receptor; Agrp, agouti-related protein; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Apoa4, apoliprotein (apo) A-IV; AST, aspartate transaminase; BW, body weight; C/EBP, CCAAT/ enhancer-binding protein; Cntfr, ciliary neurotrophic factor receptor; COMT, Catechol-O-methyltransferase; CPT-1, carnitine palmitoyltransferase-1; CRP, C-reactive protein; EGCG, epigallocatechin gallate; EX, exercise; FA, fatty acids; FASN (FAS), fatty acid synthase; FATP4, fatty acid transport protein 4; FFA, free fatty acid; FM, fat mass; FFM, fat free mass; G6PD, glucose-6-phosphate dehydrogenase; G-CSF, granulocyte colony-stimulating factor; Ghr, growth hormone receptor; Ghrl, ghrelin/obestatin prepropeptide; GK, glucokinase; GLUT4, glucose transporter type 4; GM-CSF, granulocyte-macrophage colony-stimulating factor; GPX, glutathione peroxidase; GT, green tea; GTC, green tea catechins; GTE, green tea extract; GTP, green tea polyphenols; HDL-C, high density lipoprotein-cholesterol; HF, high fat; 4-HNE, 4-hydroxynonenal; HOMA-IR, homeostasis model assessment-insulin resistance; HSL, hormone sensitive lipase; HTR, HDL-cholesterol/totalcholesterol ratio; IFN, interferon; IGF-I, insulin like growth factor-I; IGFBP-1, insulin-like growth factor binding protein-1; IL, interleukin; iNOS, inducible nitric oxide synthase; Ins1, insulin 1; IR, insulin resistance; LDL-C, low density lipoprotein-cholesterol; Lepr, leptin receptor; LF, low fat; LPL, lipoprotein lipase; LPO, lactoperoxidase; LXR, liver X receptor; MCAD, medium chain acyl coA dehydrogenase; MCD, malonyl CoA decarboxylase; MCP-1, monocyte chemoattractant protein-1; ME, malic enzyme; MPO, myeloperoxidase; MyD88, myeloid differentiation primary response gene 88; NADPH, nicotinamide adenine dinucleotide phosphate; NEFA, non-esterified fatty acid; NF-κB, nuclear factor kappa B; NO, nitric oxide; Nr3c1, nuclear receptor subfamily 3, group C, member 1; NRF1, nuclear respiratory factor 1; PAP, phosphatidic acid phosphatase; PPAR, peroxisome proliferators-activated receptor; Pref-1, preadipocyte factor-1; RER, respiratory exchange ratio; RQ, Respiratory quotient; SCD1, stearoyl-CoA desaturase-1; SGLT1, sodium-dependent glucose transporter 1; SOD, superoxide dismutase; Sort1, Sortilin 1; SREBP-1, sterol regulatory element-binding protein-1; TAG, triacylglycerol; TC, total cholesterol; TG, triglyceride; TLR, toll like receptor; TNF-α, tumor necrosis factor alpha; TRAF6, TNF receptor-associated factor 6; UCP, uncoupling protein; ↑, increase; ↓, decrease; ↔, no change. Table 4 Effect of resveratrol on obesity in in vitro, animals, and humans
First author, yr [ref] Experimental design and treatments Results
In vitro study Ahn, 2007 [87] 3T3-L1 cells treated with RSV (0, 5, 25, 50, and 100 µM) for 6 hours.
↓ TNF-α-induced PAI-1 and IL-6 production in a dosedependent manner ↑ Adipokines and adiponectin Chen, 2011 [88] 3T3-L1 cells treated with RSV (0, 10, 20, 40, and 80 µM) for 0-8 days. 
Experimental design and treatments Results
Poulsen, 2012 [121] Male Wistar rats (8-week-old) in a high-fat diet-induced obesity model. Groups including control diet group, HF group, and HF+RSV (100 mg) for 8 weeks.
↑ Hepatic TG and mitochondria content (↑ UCP-2 expression) Rivera, 2009 [122] Male obese (fa/fa) Zucker rats and lean heterozygous littermates (13-week-old). Groups including lean-control group, lean-RSV (10 mg/kg BW orally) group, obese-control group, or obese-RSV group for 8 weeks.
↓ Hepatic lipid content, TG, total cholesterol, FFA, insulin ↓ Systolic blood pressure ↓ Leptin and ↑ adiponectin ↑ Phosphorylation of AMPK and ACC ↓ TNF-α and NO production ↑ eNOS expression in VAT and aortic ring
Human
Poulsen, 2013 [123] Randomized, double-blinded, placebo-controlled trial. Healthy obese men (n=24). Groups including placebo group or RSV group for 4 weeks.
↔ Blood pressure, resting energy expenditure, oxidation rates of lipid, ectopic or visceral fat content, or inflammatory and metabolic biomarkers Timmers, 2011 [124] Randomized, placebo-controlled, double-blinded crossover study. Healthy, obese men subjects (n=11 DsbA-L, disulfide-bond A oxidoreductase-like protein; E2F1, E2F transcription factor 1; eNOS, endothelial nitric oxide synthase; ERK1/2, extracellular signal-regulated protein kinases 1 and 2; FABP4, fatty acid binding protein 4; FASN (FAS), fatty acid synthase; FFA, free fatty acid; FOXO1, forkhead box protein O1; GalR, galanin receptor ; GPX, glutathione peroxidase; GSSG, glutathione disulfide; HF, high fat; HNF-4 α , hepatocyte nuclear factor receptor-4α; HOMA-IR, homeostasis model assessment-insulin resistance; hs-CRP, high sensitivity C-reactive protein; IFN, interferon; IL, interleukin; JNK, Jun NH2-terminal kinase; IGF-I, insulin like growth factor-I; IRF, interferon regulatory factor ; IRS-1, insulin receptor substrate-1; KLF2, Kruppel-like factor 2; LPL, lipoprotein lipase; LPS, lipopolysaccharide; MCE, mitotic clonal expansion;
